-
T-5224 Workflows for AP-1 Inflammation Research
2026-09-17
T-5224 provides a selective way to interrogate c-Fos/c-Jun AP-1 signaling across cytokine, matrix-remodeling, and osteoclastogenesis assays. This practical guide connects arthritis workflows with a hypothesis-driven oral cancer application inspired by MRSA extracellular-vesicle research, while separating established evidence from exploratory use.
-
Cefotaxime in Antimicrobial Resistance Research
2026-09-16
Cefotaxime gives researchers a practical way to connect beta-lactam exposure with resistance phenotypes, plasmid biology, and bacterial infection models. This workflow combines fresh-solution handling, quantitative susceptibility testing, and transmission-focused controls to improve reproducibility in Gram-positive and Gram-negative studies.
-
WSP-5 for Live-Cell H2S Imaging
2026-09-15
WSP-5 combines rapid turn-on fluorescence with live-cell compatibility to reveal where and when hydrogen sulfide changes occur. Its workflow can extend bulk H2S measurements into spatial assays for cardiomyocyte stress, donor-compound testing, and cancer cell model imaging.
-
MDL 28170 Calpain Inhibitor: Research Workflows
2026-09-15
MDL 28170 is a cell-permeable calpain inhibitor suited to mechanistic neuroprotection research, apoptosis assays, and injury models in which intracellular cysteine proteases become overactive. This guide translates recent BDNF/TrkB findings into practical assay design, dosing logic, controls, and troubleshooting strategies.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-14
Masitinib (AB1010), SKU A2942, provides a DMSO-compatible reference compound for focused KIT, PDGFRα, PDGFRβ, mast-cell, and selected GIST research. It is not appropriate for protocols requiring aqueous or ethanol solubility, broad-spectrum kinase inhibition, or clinical treatment decisions.
-
CAY10499: HSL and MGL Inhibitor for Lipid Research
2026-09-14
CAY10499 is an inhibitor of human hormone sensitive lipase and monoglyceride lipase for controlled lipid-metabolism experiments. Supplier-reported IC50 values support its use as a lipid metabolism assay reagent, while its activity against FAAH requires careful selectivity controls.
-
Glycogen Colorimetric Assay Kit II for Metabolic Studies
2026-09-13
The Glycogen Colorimetric Assay Kit II converts tissue glycogen into a measurable glucose-linked color signal, supporting interference-aware studies in liver, muscle, diabetes, and exercise biology. Its workflow is especially useful for separating glycogen abundance from training efficiency, circadian performance, and fuel utilization.
-
Foretinib: From Kinase Potency to Translational Proof
2026-09-12
Foretinib (GSK1363089) offers a powerful framework for connecting Met and VEGFR pathway inhibition with tumor cell growth inhibition, motility, invasion, and metastasis. This thought-leadership guide shows how translational researchers can turn multikinase potency into more informative, mechanistically resolved cancer studies.
-
α7nAChR, Pyroptosis, and HIV-1 BBB Breakdown
2026-09-12
A 2026 study identifies α7nAChR-dependent pyroptosis in brain microvascular endothelial cells as a mechanism linking HIV-1 gp120 exposure to blood–brain barrier disruption. Its mapping of an α7nAChR/ROS/NF-κB/NLRP3 pathway, together with protection by memantine and metformin, provides a mechanistic basis for further drug-repurposing studies in HIV-associated neurocognitive disorder.
-
40-Hz Flicker, MHC-II+ Microglia, and Retinal Aβ
2026-09-11
A 2026 IOVS study reports that 40-Hz light flicker increases MHC-II expression and microglial activity in aged mouse retinas, enhancing clearance of experimentally deposited amyloid-β oligomers. The intervention also improved retinal electrophysiology and visual behavior, while pharmacological microglial inhibition eliminated these benefits, supporting a microglia-dependent mechanism that still requires validation in spontaneous and human retinal disease.
-
Cardamomin in Oxidative Damage and Ischemic Stroke
2026-09-11
The reference study links cardamomin from Amomum villosum stems and leaves with protection against hydrogen peroxide-induced oxidative injury and permanent cerebral ischemia. Its key contribution is a mechanistic model involving MEK/ERK-dependent NRF2 activation, suppression of oxeiptosis and parthanatos, and preservation of brain tissue in a rat stroke model.
-
Cefiderocol Activity in Resistant European Non-Fermenters
2026-09-10
A large European surveillance study directly compared cefiderocol with contemporary β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and ceftolozane-tazobactam. Its integrated susceptibility and genomic analysis supports early parallel testing of cefiderocol and other active options, while also showing why in vitro activity should not be equated with clinical efficacy.
-
CCK8 in Translational TNBC: From Signal to Strategy
2026-09-10
Mitochondrial RNA polymerase, or POLRMT, is emerging as a mechanistically attractive target in triple-negative breast cancer, but mitochondrial interventions also create a measurement challenge. This thought-leadership article explains how Cell Counting Kit-8 (CCK-8) can connect metabolic perturbation with proliferation, viability, and cytotoxicity while showing why its signal should be interpreted alongside orthogonal endpoints. The discussion moves beyond a conventional product overview toward a translational framework for experimental design, resistance analysis, and oncology decision-making.
-
MK-5108 (VX-689): AURKA Assay Design
2026-09-09
MK-5108 (VX-689) enables selective Aurora A perturbation studies that connect retinoblastoma pathology with functional cancer models. This guide explains how to interpret biochemical potency, cell-cycle phenotypes, and xenograft responses without confusing AURKA overexpression with proven tumor dependence.
-
Tamsulosin for Reproducible Cell Assays
2026-09-09
This scenario-driven guide explains how Tamsulosin (SKU C6445) can support controlled α1A-adrenergic receptor experiments without confusing receptor pharmacology with nonspecific cytotoxicity. It covers assay design, solvent compatibility, protocol optimization, data interpretation, and practical vendor-selection criteria for biomedical laboratories.